Platelet-Rich Plasma and the Best Injury Phenotype

Matching Platelet Therapy to the Right Patient for Real Results

 

PRP is one of the most discussed treatments in sports medicine right now. Doctors inject it for tendon pain, muscle tears, knee problems, and shoulder injuries. The idea sounds direct: draw your blood, spin it in a centrifuge to concentrate the platelets, inject that mixture back into the damaged tissue. But the question patients rarely hear answered honestly is — does it actually work?

Two comprehensive reviews tackled that question head-on. One published in 2021 in Therapeutic Advances in Musculoskeletal Disease, by Andia, Atilano, and Maffulli, focused on formulation and patient selection for knee conditions. The other, a 2022 systematic review by O’Dowd in the Orthopaedic Journal of Sports Medicine, analyzed trials from 2014 to 2021 covering rotator cuff injuries, tendinopathy, muscle strains, and more. Their combined conclusion was not a simple yes or no. Platelet therapy works for some injuries and some people. For others, it produces results no better than a placebo or does nothing at all after surgery. The difference comes down to injury type, patient biology, the specific PRP preparation used, and whether proper rehabilitation was part of the plan.

 

What PRP Is and How It Actually Works

Your blood contains four main components: red blood cells, white blood cells, plasma, and platelets. Most people know platelets stop bleeding. That is only part of what they do. Platelets carry growth factors — proteins that signal your body to start repairing tissue. Platelet-derived growth factor, vascular endothelial growth factor, and transforming growth factor beta are among the key players. When you concentrate platelets into a small volume of plasma, the resulting mixture is richer in these signaling molecules than normal circulating blood.

The concentration process uses a centrifuge. Depending on the technique, the final product can have platelet concentrations two to eight times higher than whole blood. Doctors then inject this mixture directly into the injured area — a tendon, a joint, a muscle tear, or in some protocols, the tissue surrounding a healing wound.

Think of it like adding a concentrated fertilizer to soil that is already trying to grow something. The injured tissue is doing its best to heal. PRP supplies extra growth factors to accelerate that process. But here is where most marketing materials stop, and where the science becomes genuinely complicated: not all PRP is the same preparation.

Some formulas include white blood cells, others exclude them. White blood cells carry inflammatory signals that can help or harm depending on the tissue environment. Some preparations activate the platelets before injection using calcium chloride or thrombin; others inject them dormant. The platelet concentration itself varies between techniques — and between individual patients, because baseline platelet counts differ.

The 2021 review by Andia et al. named this problem directly. The authors argued that the lack of standardization across PRP preparations makes it nearly impossible to compare studies. Two trials might both label their product “PRP,” but the actual formulations can be clinically different. This is one of the main reasons the overall evidence looks so mixed.

The tissue being injected also matters. Tendons are dense, poorly vascularized structures — they receive limited blood flow under normal conditions. That actually makes them candidates for PRP, because the poor blood supply limits natural healing capacity. Muscles have better circulation and recover faster on their own. Cartilage has almost no intrinsic blood supply, which makes it resistant to most regenerative approaches. To understand the full biological mechanism behind how growth factors drive this process, the article Platelet-Rich Plasma: Your Blood’s Hidden Healing Power covers the science in detail.

What the research is now pointing toward is a concept called injury phenotype matching — identifying which patient, with which specific injury, in which biological state, will actually respond to a given PRP formula. That shift in thinking changes how this treatment should be evaluated and applied.

 

Rotator Cuff Injuries: A Clear Split in the Data

The rotator cuff is a group of four muscles and their tendons that stabilize the shoulder joint. Tears range from small partial-thickness defects to complete ruptures. Both surgical and non-surgical patients have been treated with PRP, and the results split sharply depending on which group you examine.

O’Dowd’s 2022 review analyzed seven studies that added PRP during arthroscopic rotator cuff repair. All seven found no significant improvement compared to surgery alone. Pain scores, functional tests, and imaging follow-up showed no added benefit. One trial went further — it found that PRP increased markers of cell death in tendon tissue after surgery. That finding needs more investigation, but it signals that adding platelet therapy to surgical trauma may not be biologically neutral.

The picture changes entirely when PRP is used without surgery. Five out of six studies testing PRP injections as a stand-alone treatment for rotator cuff problems reported positive outcomes. Patients showed better pain relief and improved shoulder function at six months compared to those who received corticosteroid injections. One trial followed patients for two full years and found the benefits held. Another used ultrasound to document that partial tears actually reduced in size following PRP treatment.

The effects tended to peak around six months and did not always persist beyond a year in every patient. That is a realistic expectation to set — PRP is not a permanent structural repair for most people, but it can provide a meaningful window of recovery for those trying to avoid surgery.

The practical takeaway is clear: if you have a partial rotator cuff tear or chronic shoulder inflammation and want to avoid the operating room, PRP has reasonable evidence behind it. If you are already scheduled for surgery, adding PRP to the procedure will likely not change your outcome based on current data.

For a broader view of how platelet therapy fits into musculoskeletal care across multiple injury types, Platelet-Rich Plasma for Joint Pain and Sports Injuries covers the clinical applications and the underlying tissue healing mechanisms.

 

Tendons, Muscles, and Plantar Fasciitis: Sorting the Evidence

Tendinopathy — chronic tendon pain and dysfunction — affects millions of people. Common locations include the Achilles tendon at the back of the ankle, the patellar tendon below the kneecap, and the tendons around the elbow. PRP has been tested in all of these areas with inconsistent results.

For Achilles tendon pain, four studies were analyzed in O’Dowd’s review. Three found no difference between PRP and placebo injections. Patients in both groups improved, but the improvement came from time and rehabilitation — not from platelet therapy itself. One study did find benefits, but only when PRP was paired with eccentric exercises, a specific type of controlled lengthening movement with its own established evidence base. PRP alone did not work; PRP combined with structured physical therapy did. That difference matters far more than most clinical discussions acknowledge.

Tennis elbow showed a similar pattern. Two trials found that PRP offered no advantage over placebo or even whole blood injections. Patellar tendinopathy also produced no difference between PRP and saline in one study.

Gluteal tendinopathy — pain in the tendons stabilizing the hip — tells a different story. One trial found that patients who received PRP reported significantly less pain and better function at 12 weeks compared to those who got corticosteroid shots. Those benefits lasted up to two years. The corticosteroid group improved at first, then declined after six weeks. That duration difference is clinically meaningful.

For acute muscle injuries, particularly hamstring strains in athletes, the evidence is divided. Two studies found that athletes who received PRP returned to sport faster — one reported full recovery in an average of 26 days with PRP versus 42 days without. Another showed players returned six days sooner. Two other studies found no benefit at all, with identical timelines regardless of treatment. The lack of standardized PRP preparation across these trials likely explains part of the inconsistency. The article on Hamstring Injuries: The Science Behind Prevention explains why these injuries are so variable in recovery patterns and what the evidence says about reducing reinjury risk.

Plantar fasciitis showed the most consistent results of any condition in O’Dowd’s review. Two trials both found PRP superior to comparison treatments — one outperforming shockwave therapy, another outperforming corticosteroid injections at one year. Patients reported lower pain scores and better functional outcomes. The relatively stable mechanical environment of the plantar fascia may explain this. Unlike a tendon under constant dynamic load during movement, the thick fibrous band on the sole of the foot allows growth factors to work without constant disruption from weight-bearing activity.

 

Matching the Right Formula to the Right Patient

This is where the field is actually heading — and it changes how every trial result above should be interpreted.

The concept of injury phenotype refers to a specific patient profile: age, injury severity, tissue condition, inflammation level, biological markers in blood or joint fluid, and imaging findings. Two people with the same diagnosis — say, partial rotator cuff tear — can have completely different underlying biology. One may have high levels of inflammatory cytokines in the joint. The other may show minimal inflammation with primarily degenerative tissue changes. The same PRP formula may help one and do nothing for the other.

Researchers are starting to use biomarkers to predict response. In trials on knee pain and platelet therapy, patients with higher levels of specific inflammatory proteins in joint fluid showed better outcomes after PRP. That pattern suggests PRP works partly by modulating an active inflammatory process — not by generating tissue healing in the absence of any biological activity to amplify.

Imaging adds another layer of precision. Ultrasound can identify tendon thickening or increased intratendinous blood flow, both signs of active pathology that may respond to regenerative treatment. Without that baseline assessment, clinicians are making treatment decisions without knowing the tissue state they are treating.

The PRP formula itself varies more than most patients realize. According to the 2021 review by Andia et al., studies differ significantly in platelet concentration, white blood cell content, injection volume, number of injections, and whether the preparation is activated before injection. Some researchers argue that leukocyte-rich PRP performs better in certain tendon conditions, while leukocyte-poor PRP is preferable in others to avoid amplifying inflammation in an already irritated tissue environment.

Here is something worth stating plainly: some of the most widely cited negative trials in this space used preparations with platelet concentrations too low to be clinically meaningful. The product was labeled as PRP but did not meet the biological threshold the treatment requires. Negative results from poorly prepared PRP cannot be used to conclude that properly prepared PRP does not work. That methodological problem runs through much of the literature and explains why the overall picture looks so inconsistent.

The meniscus trial in O’Dowd’s 2022 review is worth separate attention. Researchers tested a technique called percutaneous trephination — creating small channels in the meniscus to improve local blood supply — followed by PRP injection into those channels. Compared to placebo, the PRP group achieved a healing rate of 52% versus 30%, and far fewer patients needed surgery afterward: 8% versus 28%. This was a single trial requiring confirmation, but the magnitude of difference is worth watching closely.

For comparison with how stem cell therapy approaches similar tissue repair questions, that article covers overlapping biology, the role of growth factor signaling, and current clinical evidence across joint conditions — including where stem cells and PRP may work better in combination than alone.

 

Rehabilitation Is Not Optional

Every study reviewed in both analyses combined PRP with some form of rehabilitation. This was not a methodological coincidence. It reflects something fundamental about how tissue healing actually works at the biological level.

Healing tissue — whether tendon, ligament, muscle, or cartilage — requires mechanical loading to remodel correctly. New collagen fibers formed during healing need to be organized along lines of functional stress. Without controlled loading, those fibers deposit randomly, producing tissue that is weaker and more prone to reinjury than the original structure. Physical therapy provides the progressive, controlled stress that guides that remodeling process.

Think of PRP as the spark and rehabilitation as the fuel. The spark alone does not keep the engine running.

The Achilles tendon data shows this directly. When PRP was tested without structured exercise, it produced no benefit over placebo. When combined with eccentric training — a loading technique with its own established evidence base for tendinopathy — results improved. PRP did not replace exercise in those trials; it added to what the exercise was already producing.

The hamstring data tells the same story. Athletes who recovered faster with PRP were also following structured rehabilitation programs with defined progression criteria. The faster return-to-play times reflected the combination of biological support and systematic physical loading, not the injection alone.

This has a practical implication that does not get communicated clearly enough. PRP is sometimes positioned as an alternative to physical therapy for people who find rehabilitation inconvenient. The evidence does not support that framing. A provider who offers PRP without a detailed post-injection loading protocol is missing the most important part of the treatment.

Research on cartilage surgery recovery and return to sport demonstrates the same principle in a different clinical context: biological intervention without structured mechanical rehabilitation consistently produces incomplete functional outcomes. Before agreeing to any platelet injection, ask for the specific rehabilitation plan — exercise type, load progression, timing, and criteria for return to activity. If those details are vague, that tells you something.

Safety data across both reviews was generally favorable. PRP uses your own blood, so immune rejection is not a concern. The most common adverse effect was temporary pain at the injection site, resolving within a few days in most cases. No serious complications were reported across the analyzed trials. The one signal that needs monitoring is the rotator cuff finding where PRP appeared to increase cell death markers in tendon tissue after surgery. That result suggests platelet therapy can be counterproductive in certain tissue environments, particularly following operative trauma.

 

What to Ask Before You Try PRP

Three questions matter most before agreeing to platelet therapy.

First: does your injury fit the profile that shows benefit in the literature? Non-surgical rotator cuff care, plantar fasciitis, and gluteal tendinopathy have the most consistent positive evidence. Achilles tendinopathy, tennis elbow, and patellar tendon pain have weaker data. Adding PRP to surgery does not appear to help based on current evidence.

Second: what is the specific preparation being used? Ask about platelet concentration, white blood cell content, activation method, injection volume, and number of sessions. A provider who cannot answer those questions with specificity is not working from a standardized protocol.

Third: what is the rehabilitation protocol following injection? Ask for the specific loading progression, the timing of exercises relative to injection, and the criteria used to advance to full activity. The evidence is consistent — PRP works in the context of structured physical therapy, not instead of it.

Even in the best-studied conditions, the effects of PRP are real but not dramatic. Recovering a few weeks faster or experiencing meaningfully less pain over 12 months represents genuine clinical value for the right patient. Biomarkers and imaging will increasingly help predict who sits in that responsive group. Until those tools are routinely used in clinical settings, careful patient selection based on injury type and biological profile remains the best available filter.

 

References

1. Andia I, Atilano L, Maffulli N. Moving toward targeting the right phenotype with the right platelet-rich plasma (PRP) formulation for knee osteoarthritis. Ther Adv Musculoskelet Dis. 2021;13:1759720X211004336.
2. O’Dowd A. Update on the use of platelet-rich plasma injections in the management of musculoskeletal injuries: a systematic review of studies from 2014 to 2021. Orthop J Sports Med. 2022;10(12):23259671221140888.